Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection (C/SOAP)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The Cesarean Section Optimal Antibiotic Prophylaxis (C/SOAP) study is a large pragmatic multi-center randomized clinical trial designed to evaluate the comparative effectiveness and safety of azithromycin-based extended-spectrum antibiotic prophylaxis (azithromycin plus standard narrow-spectrum cephalosporin) relative to standard single-agent cephalosporin prior to surgical incision to prevent post-cesarean infection.
Hypothesis: Compared to narrow-spectrum prophylaxis (i.e. cefazolin alone, or clindamycin if cephalosporin allergy) prior to surgical incision, the addition of extended-spectrum prophylaxis (azithromycin + cefazolin) reduces the incidence of post-cesarean infection.
| Condition | Intervention |
|---|---|
|
Endometritis Wound Infection Abscess Surgical Site Infection |
Drug: Azithromycin Drug: Placebo |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Prevention |
| Official Title: | Cesarean Section Optimal Antibiotic Prophylaxis Trial |
- Composite of endometritis and/or wound infection and/or other post-cesarean infections (occurring within 4 weeks of delivery) [ Time Frame: 4 weeks after delivery ] [ Designated as safety issue: No ]
- • Individual post-cesarean infections: Endometritis, wound infection (including necrotizing fascitis), other infections including abscess, septic thrombosis, pneumonia, pyelonephritis and breast infection [ Time Frame: 4 weeks after delivery ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 2000 |
| Study Start Date: | May 2011 |
| Estimated Study Completion Date: | July 2014 |
| Estimated Primary Completion Date: | January 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Placebo Comparator: Placebo
250 cc normal saline
|
Drug: Placebo
250 cc normal saline
|
| Experimental: Azithromycin |
Drug: Azithromycin
500 mg in 250 cc normal saline 1 time dose
|
Eligibility| Ages Eligible for Study: | 14 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Pregnant Women aged 14 years and over at ≥ 24 weeks' viable gestation who will undergo unscheduled/non-elective cesareans with either:
- Labor (spontaneous or induced): active labor (ongoing contractions and at least 4cm dilated or contractions for at least 4 hours with documented cervical change of ≥1cm dilatation or ≥50% effacement), or
- Membrane rupture (standardized to duration of at least 4 hours prior to randomization).
Exclusion Criteria:
- Patient unwilling or unable to provide consent
- Multiple pregnancy
- Known azithromycin (or other macrolide) allergy
- Vaginal delivery
- Elective or scheduled cesarean prior to labor or membrane rupture.
- Azithromycin, erythromycin or other macrolide antibiotic use within 7 days of enrollment.
- Clinical chorioamnionitis or any other active bacterial infection (e.g. pyelonephritis, pneumonia, abscess) at time of randomization.
- Patient is unable or unlikely to follow-up after delivery (e.g. no prenatal care or a non-resident patient)
- Fetal demise or major congenital anomaly
- Significant liver disease defined as known cirrhosis or elevated transaminases of at least 3-fold upper limit of normal
- Significant renal disease defined as serum creatinine known to be >2.0 mg/dl or on dialysis.
- Active congestive heart failure (EF<45%) or pulmonary edema
- Active diarrhea at time of delivery
- Any patient with significant electrolyte abnormalities such as hypokalemia or hypocalcemia
- Any patient with structural heart disease or arrhythmias, or taking any medications known to prolong the QT interval
- Patient currently being treated with efavirenz, nelfinavir or fluconazole
Contacts and Locations| Contact: Alan TN Tita, MD, PhD | 205-934-42565 | alan.tita@obgyn.uab.edu |
| Contact: Rachel C LeDuke, MSN | 205-934-5509 | rcopper@uab.edu |
| United States, Alabama | |
| University of Alabama at Birmingham | Recruiting |
| Birmingham, Alabama, United States, 35233 | |
| Principal Investigator: Alan TN Tita, PhD, MD | |
| United States, North Carolina | |
| University of North Carolina | Recruiting |
| Chapel Hill, North Carolina, United States, 27599-7516 | |
| Principal Investigator: Kim Boggess, MD | |
| United States, Texas | |
| University of Texas Medical Branch | Recruiting |
| Galveston, Texas, United States, 77555-0587 | |
| Principal Investigator: George Saade, MD | |
| Principal Investigator: | Alan TN Tita, MD, PhD | University of Alabama at Birmingham |
More Information
Publications:
| Responsible Party: | Alan Tita, Associate Professor, University of Alabama at Birmingham |
| ClinicalTrials.gov Identifier: | NCT01235546 History of Changes |
| Other Study ID Numbers: | F090323006, 1R01HD064729-01A1 |
| Study First Received: | November 4, 2010 |
| Last Updated: | March 27, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by University of Alabama at Birmingham:
|
Pregnancy Cesarean section Antibiotic Infections |
Additional relevant MeSH terms:
|
Abscess Endometritis Wound Infection Suppuration Infection Inflammation Pathologic Processes Pelvic Inflammatory Disease Adnexal Diseases |
Genital Diseases, Female Uterine Diseases Wounds and Injuries Anti-Bacterial Agents Azithromycin Anti-Infective Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 19, 2013